Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
1upandaway, have you made Geert aware of lenz over the years that you have been bringing him to our attention?
I sensed Geert was very heavy-hearted over the approaching fulfillment of his assessment of reinfections on those people who have already been infected two times.
If they could get a Novavax or Janssen vaccine, and an IND approval of our lenz cocktail, they may be able to prevent the third infection. At the least, if they become infected, a lenz infusion may save them.
I'd really like to hear from John Hempton about what he replied to Ruby as he did.
Ruby
@flipflapulous
·
Jul 25
Hey
@humanigen
, before you fully go belly up, can you at least release the data?? We've still never seen why we lost our entire investment in you. You owe us something. We may never get our money back, but it would be nice to have some answers.
Sincerely,
Your investors
$HGEN
John_Hempton
@John_Hempton
·
Jul 27
because you were defrauded.
cowtown jay
@cowtown_jay
I think lenz trial data is under regulatory review for covid, CMML, and GvHD approvals or CMA's. Do you disagree? If you accepted Cameron's meeting invitation, did you learn something that convinces you that he has defrauded investors? I'd like to hear your opinion. Thank you.
I think lenz trial data is under regulatory review for covid, CMML, and GvHD approvals or CMA's. Do you disagree? If you accepted Cameron's meeting invitation, did you learn something that convinces you that he has defrauded investors? I'd like to hear your opinion. Thank you.
— cowtown jay (@cowtown_jay) July 30, 2023
"Note: I think I need to look more closely at Acute GvHD. This could be the dark horse winner of lenzilumab's first authorization or approval. Partnership interest. TeraImmune TReg work. Phase 2/3 trial."
It does indeed look like there could be reason to hope for good news regarding the use of lenz in the prevention and treatment of Acute Graft Versus Host Disease.
"Humanigen Announces Clinical Trial Collaboration to
Evaluate Lenzilumab in Acute Graft Versus Host Disease
11/11/2021
Humanigen is supporting the University of Birmingham to conduct a Phase 2/3, potentially registrational, clinical trial at IMPACT stem cell transplant centers across the United Kingdom
The “Risk Adapted Therapy in Acute GvHD”, or “RATinG”, study is expected to begin enrolling in 1H22"
https://s28.q4cdn.com/539885110/files/doc_news/Humanigen-Announces-Clinical-Trial-Collaboration-to-Evaluate-Lenzilumab-in-Acute-Graft-Versus-Host-Disease-2021.pdf
Humanigen will also advance its plan to study lenzilumab in acute graft versus host disease ("aGvHD") that occurs in patients undergoing bone marrow transplant, which will be the focus of the RATinG study that is expected to enroll its first patient in 3Q22.
https://www.newsfilecorp.com/release/131903/Humanigen-Implements-Strategic-Realignment-of-Pipeline-and-Resources-to-Achieve-Key-Clinical-Milestones
"Continuing to execute the RATinG study for lenzilumab for the early treatment of aGvHD with the goal of reporting a planned interim assessment of the first 20 patients in 2Q23"
https://www.newsfilecorp.com/release/131903/Humanigen-Implements-Strategic-Realignment-of-Pipeline-and-Resources-to-Achieve-Key-Clinical-Milestones
See also the corporate preentation (thru pg 15)
https://ir.humanigen.com/English/events-and-presentations/default.aspx
This could also explain why Humanigen is keen on partnering/combining with PCI, for their services in the UK.
https://pci.com/humanigen-preparations-for-commercialization/
In addition, it appears that the company is moving forward partnering/combining with Baudax/TeraImmune.
"TeraImmune develops cell therapeutics for autoimmune diseases and immune-related disorders. It uses regulatory T (Treg) cells from a donor and makes cells for hemophilia, multiple sclerosis, and graft-versus-host disease from stem cell transplantation, enabling the healthcare industry to suppress unwanted immune reactions without side effects in patients with autoimmune diseases. The company was founded in 2016 and is based in Germantown, Maryland. In June 2023, TeraImmune was acquired by Baudax Bio. The terms of the transactions were not disclosed."
https://www.cbinsights.com/company/teraimmune
Also, this indication could relate to our latest patent
"Method of increasing the efficacy of CAR-T immunotherapy using lenzilumab
Patent number: 11673962
Abstract: Methods of inhibiting or reducing the incidence or the severity of immunotherapy-related toxicity in a subject, the method comprising a step of administering a recombinant hGMCSF antagonist to the subject, wherein said administering inhibits or reduces the incidence or the severity of immunotherapy-related toxicity in said subject, are provided. An hGMCSF antagonist for use in methods of inhibiting or reducing the incidence or the severity of immunotherapy-related toxicity in a subject also are provided.
Type: Grant
Filed: October 2, 2018
Date of Patent: June 13, 2023
Assignee: HUMANIGEN, INC.
Inventors: Cameron Durrant, Dale Chappell"
Notice the 2018 file date, well before covid.
https://patents.justia.com/assignee/humanigen-inc
Welcome to the room, Timing101. I'm glad you liked my summary, also.
Thank you and good luck to you as well. I really think we're seeing management execute an effective strategy to safeguard us and to force their desired outcome. I was very happy to add here.
That's a risk with this strategy. I have VERY minimal risk by adding at this price point, based on the 8-Jay.
I was able to just about double my position by adding at $0.013755.
I still have a very small number of shares. But I was glad to buy them before Cam and Dale get ready to spring some good news on us.
ZoomLenz . 2 of 2 . Synopsis. Topical Focus on Top Ihub>>Twitter posts
Subject: Market Opportunity
Note: I think I need to look more closely at Acute GvHD. This could be the dark horse winner of lenzilumab's first authorization or approval. Partnership interest. TeraImmune TReg work. Phase 2/3 trial.
"There will be a plethora of indications for lenz once it is approved and becomes known to the medical community. Add to that HGEN005...and ifabotuzumab..."
"Gilead's Magrolimab strikes out as blood cancer treatment...azacitidine..."
"If Gilead is scrapping their late-stage study of magrolimab with azacitidine to treat blood cancer, I wonder how that bodes for the other half dozen or so trials using that drug combination."
"The United States represents 4.23% of the world's population.
US percentage of (covid) cases 15.3%
US percentage of (covid) deaths 16.3%
It doesn't have to be that way, not when products from Humanigen, Novavax, Janssen, and Innovation, may stand ready to be used as components of a real vaccine cocktail."
"When we were naively thinking that LIVE-AIR's phenomenally successful trial outcome would result in an EUA, and could yield a market cap in the $20B range, we had reason to think that...Novavax had attained that level."
"I expect that we will benefit far more without a Gilead alliance...keep away from large market cap entities, and let the shareholders be the beneficiaries of the company's success."
"...valuation will prove far too low as the medical community becomes familiar with the value of lenzilumab's unique method of action."
Subject: Stock Play
"...our float is 229,164,012 shares, which is 192.45% of our 119,080,135 issued share total...Failures to Deliver (FTD's). Do we really want to issue additional shares for that purpose? Or do we just want paid to close out those open positions?"
"I wouldn't be surprised if we were actually under TWO business combination contracts, with PCI and with Baudax."
"Rule 204 Close-out Requirement. Rule 204 requires brokers and dealers that are participants of a registered clearing agency to take action to close out failure to deliver positions. Closing out requires the broker or dealer to purchase or borrow securities of like kind and quantity."
"I'm glad to see the Baudax/TeraImmune slide presentation features Recro staff as members of their Senior Management Team."
"I think a stock split is going to require that ALL shares outstanding be split 5:1. Illegal shorts will have to deliver 5 shares for every 1 they shorted."
"...the float of 229,164,012 was 192.45% of our current OS...So that's 110M shares more in the float, than in the OS."
"I should also consider that PCI Pharma may still be a targeted business combination."
"Baudax investment. It looks like we may have played a major role in financing their acquisition of TeraImmune by buying those 500K shares..."
"Why would we have funded Baudax's acquisition of TeraImmune, if we did not plan to merge with them?"
"I don't know what management's plan is in regards to Failures to Deliver, but I'm glad they are astute enough to manage this situation themselves..."
"less Ihub access to HGEN information...No information is provided on Shares in Issue or Float."
Subject: Influences
"I never understood why Hohneker and Xie were appointed to the board..."
"I don't (want) my taxpayer dollars to provide funding to Pfizer, if they are interfering with lenzilumab's authorization to prevent millions of deaths that their covid vaccines won't save."
"I hope Geert continues to communicate in videos.
But his comments regarding poor projected outcomes starting late this season, or early next season, for twice re-infected covid patients, is ominous."
""How is resigning at the same time, causing a Nasdaq non-conformance for the company, the faithful execution of their obligated Duty of Care?"
Initial "ZoomLenz" post
"Hohneker and Xie joined the BOD at the same time, and resigned on consecutive days."
"I think proof of our sabotage is in evidence already.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169869278
LIVE-AIR only included patients in disease severity scales 4 or 5. ACTIV-5 included patients in disease severity scales 5, 6, and 7."
Mojocash, is your trading platform showing Bid and Ask data as normal, or are you just getting access to that information from a trading ticket?
One of these things is not like the other, on Ihub, anyway. Compare data available to see that we now have less Ihub access to HGEN information. I'll use the Ford data to illustrate.
Price, support, resistance
Ford: https://ih.advfn.com/stock-market/NYSE/ford-motor-F/chart
HGEN: https://ih.advfn.com/stock-market/USOTC/humanigen-HGEN/chart
Note that on the bottom right of the matrices are links for "more quote information." Click on those links, and you get
Ford: https://ih.advfn.com/stock-market/NYSE/ford-motor-F/stock-price
Data displayed includes Shares in Issue and Float
HGEN: https://ih.advfn.com/stock-market/USOTC/humanigen-HGEN/stock-price
No information is provided on Shares in Issue or Float. There is also no longer a link at the bottom right of the matrix, as there still is for Ford, to access "more financial information." Here is the additional data for Ford from that link.
Ford: https://ih.advfn.com/stock-market/NYSE/ford-motor-F/financials
We have trading platforms. We have access to some of the data that Ihub now deprives us of.
But okay, it is what it is, and we can deal with it anyway.
But for the record, it makes more sense to regain Nasdaq listing requirements for two companies, instead of one, in my opinion. Why duplicate the process?
I continue to be impressed with the company's navigation through this process. I didn't know how they were going to reflect $22B worth of FTD's on a term sheet, anyway. LOL!
"Time" is my biggest resource constraint. We've got an unprecedented price explosion and it's hard to wait to see that happen. But the unfolding strategy being enacted has locked our adversary out of action they would have otherwise attacked us with. Brilliant!
This was my first attempt to trade during normal trading hours (for almost everybody but us) on Schwab. TDAmeritrade gave Schwab their trading accounts. I've been able to place trades after hours, even a $100 sell order is accepted. TDA wouldn't have accepted that. So, good and bad on Schwab. But I'll keep E*Trade in mind once I get to see how this goes with Schwab. Just not a good initial impression. Thanks for the suggestion!
I tried to more than double my small position today at $0.0165, which was then the Ask.
The account balance showed my deposit yesterday was Available to Trade on my new Schwab account. But after about 20 minutes of chatting with tech support, he told me that I had to wait till Monday.
The company is not going to forward split shares they did not issue.
I can understand not being too happy.
But, one type of insolvency proceeding is a restructuring, which may include a merger.
https://www.chamberlain-co.co.uk/stages-of-insolvency/
I think this is clearly the path we are on. In evidence of that was our purchase of 500K shares of Baudax Bio on June 30th, which was when Baudax acquired TeraImmune. And TeraImmune also focuses on suppressing immune response, while Baudax has a small CDMO it is associated with. Good framework to build upon.
And no one has mentioned that Humanigen could very well own every share they have issued, which I think they do. I think we are poised to initiate a forward stock split with our merger, and cause a short squeeze.
As you noted, the company is "...exploring all restructuring options..." Why would we have funded Baudax's acquisition of TeraImmune, if we did not plan to merge with them?
Just my opinion, with just enough subtle substantiation for me to comfortably make that conclusion.
"How is resigning at the same time, causing a Nasdaq non-conformance for the company, the faithful execution of their obligated Duty of Care? Can the company seek to enjoin them from resigning, until new Board Members can be appointed? What is their collective liability for this breach of their fiduciary duty?
This is highly suspicious."
While the questions I asked could be legitimate, there could also be a benign explanation. In fact, I hope there is.
I know some of you also post on Twitter. Can any of you tell me who designates the "Top" posts there on Humanigen's investor board? Is it a company representative or associate? I'm going to share this post on Twitter, and if no one here knows who controls that board, maybe someone on Twitter will be able to answer my question.
Uhhhh, no, not spam.
Thanks, Yooo. Here's more.
"On July 24, 2023, Baudax Bio, Inc. (the “Company”) received a determination from the Nasdaq Hearings Panel (the “Panel”) granting the Company’s request for the continued listing of its common stock on The Nasdaq Stock Market (“Nasdaq”), subject to the Company evidencing compliance with all applicable criteria for initial listing on The Nasdaq Capital Market, and certain other interim conditions."
https://www.sec.gov/Archives/edgar/data/1780097/000119312523192792/d538486ddefa14a.htm
The BOD resignations were, "...not the result of disagreements with Humanigen on any matter relating to Humanigen's operations..."
Could be right. Or it could be they disagreed with the Baudax investment. It looks like we may have played a major role in financing their acquisition of TeraImmune by buying those 500K shares, which got as high as $1.40 that day. Stock-for-stock deal, but operating costs will likely be higher for them..
And sacrificing the Nasdaq listing? Maybe we did that, and maybe the Board members resigned, because we are going to form our business combination with Baudax, and there weren't enough Board seats in the deal. They're a small outfit, and also facing delisting, if they can't regain compliance. And the Founder also founded Recro Bio REPH.
"RECRO COMPLETES SEPARATION OF BAUDAX BIO AND BECOMES A DEDICATED CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION
NOVEMBER 21, 2019 4:30PM EST"
https://ir.societalcdmo.com/press-releases/detail/153/recro-completes-separation-of-baudax-bio-and-becomes-a
Limited resources. A small operation. But an established framework, and potential to grow.
Maybe it's just wishful thinking, because to say I've been doing a lot of that would be a huge understatement. But dang! We're on the cusp of turbo-blasting, and I want to see it happen!
Here's the patent information in an easier to read format, including the patent you are bringing to our attention, and which is appreciated.
I don't remember seeing your name here before. So welcome to the room, if this is your first visit.
https://patents.justia.com/assignee/humanigen-inc
I'm glad to see the Baudax/TeraImmune slide presentation features Recro staff as members of their Senior Management Team.
Maybe the Board didn't like moving on them, but I sure do, if our IP moves/stays with us
https://www.sec.gov/Archives/edgar/data/1780097/000119312523187635/d518975ddefa14a.htm
I was making a valid point about Item 5.02. Do you care to address my point, or just waste my time?
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On July 18, 2023, John Hohneker resigned from the Board, and on July 19, 2023 Cheryl Buxton and Kevin Xie both resigned from the Board, in each case with immediate effect. The decisions of Dr. Hohneker, Ms. Buxton and Mr. Xie to resign were not the result of disagreements with Humanigen on any matter relating to Humanigen's operations, policies or practices.
https://www.sec.gov/ix?doc=/Archives/edgar/data/1293310/000121465923009927/j7242308k.htm
Members of the board Title Age Since
Kevin Yili Xie Director/Board Member 53 2021
Rainer Boehm Director/Board Member 62 2018
Ronald Barliant Director/Board Member 77 2016
Cheryl Buxton Director/Board Member 63 2019
Cameron Durrant Chairman 62 2016
Omar Ahmed Chief Tech/Sci/R&D Officer - 2020
Dale B. Chappell Director/Board Member 52 2021 (as early as 2016?)
John Hohneker Director/Board Member 63 2021
https://www.marketscreener.com/quote/stock/HUMANIGEN-INC-25805137/company/
Hohneker and Xie joined the BOD at the same time, and resigned on consecutive days.
https://www.businesswire.com/news/home/20211020005343/en/Humanigen-Elects-John-Hohneker-MD-and-Kevin-Xie-PhD-to-Board-of-Directors
The problem I have is that Board Members have a fiduciary duty, including a Duty of Care to shareholders and the company.
https://www.cooleygo.com/director-fiduciary-duties/#:~:text=Directors%20have%20fiduciary%20duties%20of,the%20Company%20and%20evaluating%20opportunities.
How is resigning at the same time, causing a Nasdaq non-conformance for the company, the faithful execution of their obligated Duty of Care? Can the company seek to enjoin them from resigning, until new Board Members can be appointed? What is their collective liability for this breach of their fiduciary duty?
This is highly suspicious.
You can search my posting history for their names, Yooo. I have always said that I didn't know why Honecker and Xie were appointed to the board.
I can't comment on their appointment to the board. I just never understood it, whether it was good or bad.
I just transferred enough money from my bank to be able to double my position. With this new Schwab account, it looks like the money may not clear until tomorrow.
I never understood why Hohneker and Xie were appointed to the board. Their resignations, along with Cheryl Buxton's, caused the additional Nasdaq non-conformance.
https://www.sec.gov/ix?doc=/Archives/edgar/data/1293310/000121465923009927/j7242308k.htm
I haven't seen any email, News update on the company site, not even a tweet.
I see this, though, in answer to you question.
"Nasdaq plans to delist the stock from its Capital Market and suspend trading from Wednesday. Trading will switch to the OTC Pink Market, with Humanigen telling investors the delisting will harm its ability to raise money. Investors responded by sending shares in Humanigen down 72% to just five cents in pre-market trading."
https://www.fiercebiotech.com/biotech/humanigen-mulls-bankruptcy-after-reverse-merger-falls-through
This isn't the first time Nasdaq has done this to us. They delisted us before when we still had time to regain compliance. I think that was in 2017.
I just now read what Preciouslife1 posted, Newtg.
Did Nasdaq strike again? We should have 27 more days to regain compliance.
I'm surprised to see Cheryl resign.
There has been recent heated debate here regarding vaccines.
I don't have a personal stake in the issue, because I think my immune response system was programmed to respond appropriately 50 years ago, when I had a severe case of mononucleosis, and I now see that my daughters and granddaughter may have inherited that immune response system. My family and I are largely not vaccinated and have not been diagnosed with coronavirus (my youngest daughter did have 1 vaccine dose).
But I have long suspected that the coronavirus was subjected to gain of function research, with the goal of using the virus as a bioweapon. We're seeing confirmation of that in on-going House committee hearings. But it was suspected to be the case for years now.
"China is collecting the world’s DNA and the reason is sinister...
December 4, 2020
Gordon Chang warns next disease could be far more deadly than COVID-19...
China's reasons for wanting this information involve dominating the biotechnology industry which “is very important to them,” said Chang.
“They included it in their ‘Made in China 2025’ initiative, he pointed out, “which is a decade long program to dominate certain industries.”
The second reason is something much more sinister, “China is probably trying to develop diseases that target not just everybody, but target only certain ethnic or racial groups.”
https://www.foxnews.com/world/china-collecting-worlds-dna-sinister
Before dismissing this because of the Fox News link, consider the following facts.
The United States represents 4.23% of the world's population.
https://www.worldometers.info/world-population/population-by-country/
https://www.worldometers.info/world-population/
When the Johns Hopkins Coronavirus Research Center quit updating their platform in March of this year, the cumulative coronavirus cases and deaths were as follows.
US covid cases 103,804,263/
total covid cases 676,609,955
US percentage of cases 15.3%
US covid deaths 1,123,836/
total covid deaths 6,881,955
US percentage of deaths 16.3%
https://coronavirus.jhu.edu/map.html
In terms of vaccinated versus unvaccinated, I don't think an argument can be made, because there IS NO VACCINE.
I think Humanigen's lenzilumab is going to change that, when it is used in our patented cocktail of lenz with polyclonal antibodies, an anti-viral such as brilacidin, and a traditional vaccine, such as made by Novavax and Janssen.
The Big Pharma and mRNA proponents have to at least recognize the variant-specific limitations of their products and technology, and realize that the world's therapeutic arsenal is non-existent.
It doesn't have to be that way, not when products from Humanigen, Novavax, Janssen, and Innovation, may stand ready to be used as components of a real vaccine cocktail.
Magrolimab was 47's lead product. Good for 47 to have perhaps benefitted by the acquisition more than they might have benefitted by remaining independent.
But I see absolutely no comparison to lenz and Humanigen, and I expect that we will benefit far more without a Gilead alliance. I think Durrant and Dale are entrepreneurs, and that's a fire that you just can't put out once it starts burning.
I want our revenue to light up our earnings per share, and our most effective way to realize that is to keep away from large market cap entities, and let the shareholders be the beneficiaries of the company's success.
If Gilead is scrapping their late-stage study of magrolimab with azacitidine to treat blood cancer, I wonder how that bodes for the other half dozen or so trials using that drug combination.
https://clinicaltrials.gov/search?intr=Magrolimab&viewType=Table&page=1
Lenzilumab with azacitidine was the drug combination that resulted in our successful CMML study.
https://www.newsfilecorp.com/release/169164/Humanigen-Presents-Promising-New-Hematologic-Data-from-PREACHM-Trial-for-Chronic-Myelomonocytic-Leukemia-Treatment-at-the-2023-European-Hematology-Association-Congress
"Canadian Investment Regulatory Organization (CIRO) is the recognized SRO to operate as a successor to the Investment Industry Regulatory Organization of Canada (IIROC) and the Mutual Fund Dealers Association of Canada (the MFDA). IIROC and the MFDA amalgamated to continue as the New Self-Regulatory Organization of Canada (New SRO), effective January 1, 2023, which subsequently changed its name to CIRO on June 1, 2023."
https://www.osc.ca/en/industry/market-regulation/self-regulatory-organizations-sro/predecessor-self-regulatory-organizations/investment-industry-regulatory-organization#:~:text=IIROC%20and%20the%20MFDA%20amalgamated,CIRO%20on%20June%201%2C%202023.
In my experience, the US government's abuse of discretionary authority was never more clearly illuminated than when my former focus company, SpongeTech, would introduce an Original Issuance of Shares (OIS) to a group of investors who were located in both the US and in Canada.
IIROC came down hard on everybody involved: the clearing firm; the brokerage; and the individual broker.
For the most part, there wasn't a peep from the American Self-Regulatory Organizations (SROs) such as the Nasdaq, FINRA, or the SEC, for the protection of American investors who received shares from that very same block of shares issued by the company.
I was able to subpoena FINRA's Electronic Blue Sheets (EBS) trading records, which showed tens of millions of shares naked shorted every day. And the primary clearing firm SPNG used, Penson Financial (which came our of nowhere and had quickly become the country's 3rd largest financial firm), declared bankruptcy. The SEC also ended up, finally, charging Penson with naked shorting. Here is info for anyone interested.
https://www.sec.gov/news/press-release/2014-101
https://www.sec.gov/litigation/admin/2015/33-9914.pdf
Of note, though, is this:
"The Commission will hold funds paid pursuant to this Section in an account at the United
States Treasury pending a decision whether the Commission, in its discretion, will seek to
distribute funds or, subject to Exchange Act Section 21F(g)(3), transfer them to the general fund of
the United States Treasury."
from the 2nd link, page 23
The SEC is chartered to protect the investing public, and to return disgorged funds to injured investors. They should add a sentence clause to that mandate, "if they want to." They didn't want to restore injured investors against an informally associated individual here.
I don't know what management's plan is in regards to Failures to Deliver, but I'm glad they are astute enough to manage this situation themselves, by the design of their share structure, and I look forward to a 5:1 forward stock split, and a stock-for-stock merger, or two.
I wouldn't be surprised if we were actually under TWO business combination contracts, with PCI and with Baudax.
"...Baudax equity holders immediately prior to the acquisition will own approximately 18% of the combined Company..." formed with TeraImmune.
https://www.baudaxbio.com/news-and-investors/press-releases/detail/267/baudax-bio-acquires-teraimmune-inc
A similar equity ownership in PCI and Baudax-related business combinations would still give us majority control of Humanigen.
And just because whatever your group heard hasn't come to pass as expected, doesn't mean that it won't come to pass. I think the company must have positive regulatory decisions from Australia, or we would not have proceeded with our investment in Baudax. And our boys are like a dog with a bone when it comes to PCI. They won't let it go.
If you watched Geert's video that 1up shared with us today, vaccinated but re-infected patients could be facing a deadly prognosis when the inevitable, more virulent strain of covid begins to circulate in the coming months. The mutation of that deadly virus strain will be foreshadowed by increased "excess deaths" in covid-associated indications, as you mentioned.
You told Ruff to, "average down while the averages remain good, not gonna last."
Now you're saying that management has to get this drug going and quickly.
I thought you were within hearing distance of a source. These statements are contradictory, and I don't know how to consider them.
I hope Geert continues to communicate in videos.
But his comments regarding poor projected outcomes starting late this season, or early next season, for twice re-infected covid patients, is ominous. They need the lenz/vaccine/anti-viral cocktail NOW. At the least, they will need a lenz therapeutic infusion very soon after they become re-infected a third time.
Will ANYTHING force the US FDA to quit riding a dead horse, and give lenzilumab all the resources and support necessary to make sure this country is protected?
I'm sharing your link on Twitter, 1upandaway, and thank you for bringing it to our attention.
https://rumble.com/v2zt5n0-assuming-my-predictions-are-correct-who-will-be-at-risk-and-who-will-not.html
Gilead's Magrolimab strikes out as blood cancer treatment.
I think we will once again see the ultra value lenz has to enhance the efficacy of the primary treatment therapeutic, in this case, azacitidine, which is being used in our trial as well.
https://www.reuters.com/business/healthcare-pharmaceuticals/gilead-stops-late-stage-trial-blood-cancer-treatment-2023-07-21/#:~:text=July%2021%20(Reuters)%20%2D%20Gilead,it%20would%20not%20be%20effective.
I gave you the ZoomLenz version of progress.
"I think that the supportive data that can be harvested from the ACTIV-5 final report, coupled with the CMML study findings, and including our possibly comparable results to Gohibic in treating stage 6 patients (ACTIV-5 treated stage 5 AND 6 patients), that the FDA may find enough safety and efficacy data to make a favorable decision on approving a resubmitted EUA application."
I know management is planning to update our progress to regulators overseas, also, and that may be more likely to get approval. Pfizer owns the FDA.